Inspyr Therapeutics, Inc. Share Price Other OTC
Equities
NSPX
US45782A4031
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 241K 19.13M |
---|---|---|---|---|---|
Net income 2021 | 2M 159M | Net income 2022 | -1M -79.37M | EV / Sales 2021 | - |
Net cash position 2021 | 197K 15.64M | Net Debt 2022 | 305K 24.21M | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.4
x | P/E ratio 2022 |
-0.23
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 10/10/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Ogilvie
BRD | Director/Board Member | 69 | 31/01/08 |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 11/10/16 |
1st Jan change | Capi. | |
---|---|---|
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |